




版權說明:本文檔由用戶提供并上傳,收益歸屬內容提供方,若內容存在侵權,請進行舉報或認領
文檔簡介
NCCNClinicalPracticeGuidelinesinOncologyNCCNGuidelines?)KidneyCancerersionJuneNCCNGuidelinesforPatients?availableat/patientsVersion1.2023,06/17/22?2022NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.PrintedbyMinTangon6/19/202210:53:22AM.Forpersonaluseonly.Notapprovedfordistribution.Copyright?2022NationalComprehensiveCancerNetwork,Inc.,AllRightsReserved.*RobertJ.Motzer,MD/Chair?T*EricJonasch,MD/Vice-chair?TheUniversityofTexasNeerajAgarwal,MD??AjjaiAlva,MBBS?UniversityofMichiganRogelCancerCenterMichaelBaine,MD,PhD§Fred&PamelaBuffetCancerCenterKathrynBeckermann,MD,PhD?Vanderbilt-IngramCancerCenterMariaI.Carlo,MD?ToniK.Choueiri,MD?TCancerCenter|MassachusettsGeneralHospitalCancerCenterBrianA.Costello,MD,MS?IthaarH.Derweesh,MDωcerCenterArpitaDesai,MD?TUCSFHelenDillerFamilyCenterYasserGed,MBBS?hensiveCancersSabyGeorge,MD?RoswellParkComprehensiveCancerCenteresPanelDisclosuresJohnL.Gore,MD,MSωSeattleCancerCareAllianceNaomiHaas,MD?nterStevenL.Hancock,MD§TPayalKapur,MD≠CenterChristosKyriakopoulos,MD?UniversityofWisconsinCarboneCancerCenterElaineT.Lam,MD?UniversityofColoradoCancerCenterPrimoN.Lara,MD?UCDavisComprehensiveCancerCenterClaytonLau,MDωCityofHopeNationalMedicalCenterDavidC.Madoff,MD∩YaleCancerCenter/SmilowCancerHospitalBrandonManley,MDωMoffittCancerCenterM.DrorMichaelson,MD,PhD?CancerCenter|MassachusettsGeneralHospitalCancerCenterAmirMortazavi,MD?eCancerCenterJamesCancerHospitalLakshminarayananNandagopal,MD?O'NealComprehensiveCancerCenteratUABElizabethR.Plimack,MD,MS?TFoxChaseCancerCenterLeePonsky,MDωhensiveCancerCenterSundharRamalingam,MD?BrianShuch,MDωCLAJonssonComprehensiveCancerCenterZacharyL.Smith,MDωSitemanCancerCenteratBarnes-JewishHospitalandWashingtonUniversitySchoolofMedicineJeffreySosman,MD?garwalPhDiPhDchonfeldBA?Medicaloncology¥Patientadvocacy§Radiotherapy/Radiationoncology*DiscussionwritingcommitteememberanelMembersyoftheGuidelinesUpdateslowUpforStageIIIIKIDanelMembersyoftheGuidelinesUpdateslowUpforStageIIIIKIDKIDeatmentKIDgeryKIDABSystemicTherapyforRelapseorStageIVDiseaseKIDCCarcinomaCriteriaforFurtherGeneticRiskEvaluationforHereditaryRCCSyndromes(HRCC-1)HereditaryRCCSyndromesOverview(HRCC-2)GeneticTesting(GENE-1)Kidney-SpecificScreeningRecommendationsforPatientswithConfirmedHereditaryRCC(HRCC-B)Kidney-SpecificSurgicalRecommendationsforPatientswithConfirmedHereditaryRCC(HRCC-C)Kidney-SpecificSystemicTherapyforPatientswithConfirmedHereditaryRCC(HRCC-D)Abbreviations(ABBR-1)dexlievesthatthebestmanagementforanypatientwithcancerisinaclinicaltrial.Participationinclinicaltrialsisespeciallyencouraged.FindanNCCNMemberInstitution:/home/member-institutions.fEvidenceanddationsotherwisedNCategoriesofEvidenceandConsensus.NCCNCategoriesofPreference:Allrecommendationsareconsideredappropriate.SeeNCCNCategoriesofPreference.TheNCCNGuidelinesareastatementofevidenceandconsensusoftheauthorsregardingtheirviewsofcurrentlyacceptedapproachestotreatmentAnyclinicianseekingtoapplyorconsulttheNCCNGuidelinesisexpectedtouseindependentmedicaljudgmentinthecontextofindividualstancestodetermineanypatientscareortreatmentTheNationalComprehensiveCancerNetworkNCCNmakesnorepresentationsorwarrantiesofanykindregardingtheircontentuseorapplicationanddisclaimsanyresponsibilityfortheirapplicationoruseinanywayTheNCCNbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.?2022.Version1.2023,06/17/22?2022NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.PrintedbyMinTangon6/19/202210:53:22AM.Forpersonaluseonly.Notapprovedfordistribution.Copyright?2022NationalComprehensiveCancerNetwork,Inc.,AllRightsReserved.dexsionoftheNCCNGuidelinesforKidneyCancerfromVersioninclude?AdjuvantTreatmentpPathway2revised:"Clinicaltrial"removed.pBottompathway?Clearcellhistologyrevised:"Clinicaltrial(preferred)"removed.?Non-clearcellhistologyrevised:Surveillanceorclinicaltrial?TreatmentforRelapseorStageIVpClearcellhistology?4thlinerevised:"...MetastasectomyorSBRTorablativetechniquesforoligometastaticdiseaseorMetastasectomywithcompleteresectionofdisease,followedbyadjuvantpembrolizumabwithin1yearofnephrectomy."?DiseaseProgressionforRelapseorStageIVpClearcellhistology?Bottomlineadded:"...BestsupportivecareorMetastasectomyorSBRTorablativetechniquesforoligometastaticdisease."(AlsoforNon-clearcellhistology)?PrinciplesofSurgerypBullet6,sub-bullet3revised:AblativetechniquesareassociatedwithahigherlocalrecurrenceratethanconventionalsurgeryandmayrequiremultipletreatmentstoachievethesamelocaloncologicoutcomesasconventionalsurgeryKID-C(1of2)?PrinciplesofSystemicTherapyforRelapseorStageIVDiseasepSubsequentTherapyforClearCellHistology?PreferredRegimens–Lenvatinib+everolimuswaschangedtoacategory2Arecommendation.?OtherRecommendedRegimens–Tivozanibwaschangedtoacategory1recommendation.?UsefulinCertainCircumstances–Belzutifanwasaddedasacategory2Brecommendation.Version1.2023,06/17/22?2022NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.UPDATESUPDATESVersion1.2023,06/17/22?2022NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.PrintedbyMinTangon6/19/202210:53:22AM.Forpersonaluseonly.Notapprovedfordistribution.Copyright?2022NationalComprehensiveCancerNetwork,Inc.,AllRightsReserved.dexsionoftheNCCNGuidelinesforKidneyCancerfromVersionincludeKID-C(2of2)?SystemicTherapyforNon-ClearCellHistologypOtherRecommendedRegimens?Nivolumab+cabozantinibwasaddedasacategory2Arecommendation.pUsefulinCertainCircumstances?Nivolumab+ipilimumabwasaddedasacategory2Brecommendation.?Footnotehrevised:Forcollectingductormedullarysubtypes,partialresponseshavebeenobservedwithcytotoxicchemotherapy(carboplatin+gemcitabine,carboplatin+paclitaxel,orcisplatin+gemcitabine)andotherplatinum-basedchemotherapiescurrentlyusedforurothelialcarcinomas.Gemcitabine+doxorubicincanalsoproduceresponsesinrenalmedullarycarcinoma(RMC)(WilsonNR,etal.ClinGenitourinCancer2021;(6)19:e401-e408RoubaudG,etal.Oncology2011;80:214-218;ShahAY,etal.BJUInt2017;120:782-792).Oraltargetedtherapiesgenerallydonotproduceresponsesinpatientswithrenalmedullarycarcinoma(RMC);erlotinib+bevacizumabcanproduceresponseseveninheavilypretreatedpatientswithRMC.Outsideofclinicaltrials,platinum-basedchemotherapyregimensshouldbethepreferredfirst-linetherapyforrenalmedullarycarcinomaRMC.?CriteriaforFurtherGeneticRiskEvaluationforHereditaryRCCSyndromespBullet2revised:AnindividualwithRCCoranindividualunaffectedwithanyofthefollowingcriteriapColumn2,bottompathwayrevised:"...Refertospecificsyndromes-SeeHereditaryRCCSyndromesOverview(HRCC-2),SeeNCCNGuidelinesforGenetic/FamilialHigh-RiskAssessment:Breast,Ovarian,andPancreatic:PrinciplesofCancerRiskAssessmentandCounseling(EVAL-A)andPedigree(EVAL-B)"spFootnotecadded:Ifunaffected,whenpossible,testfamilymemberwithhighestlikelihoodofapathogenic/likelypathogenicvariantbeforetestinganunaffectedindividual.pFootnotedadded:UnnecessaryintranslocationalRCCormedullaryRCC.?Footnote4added:BelzutifanisFDA-approvedforthetreatmentofVHL-associatedRCC,centralnervoussystem(CNS)hemangioblastomas,orpNETnotrequiringimmediatesurgery.?Footnote5added:JonaschE,DonskovF,IliopoulosO,etal.BelzutifanforRenalCellCarcinomainvonHippel–LindauDisease.NEnglJMed2021;385:2036-2046.ABBR-1?Newsectionadded:AbbreviationsultiplerenalonsidergeneticevaluationSeeereditaryRenalCellCarcinomasHRCC1)urothelialcarcinomaPrintedbyMinTangon6/19/202210:53:22AM.Forpersonaluseonly.NotapprovedultiplerenalonsidergeneticevaluationSeeereditaryRenalCellCarcinomasHRCC1)urothelialcarcinomadexusINITIALWORKUPHP?CBCwithdifferential,comprehensivemetabolicpanel,LDHbdominalbdominalpelvicCTa?CTchesta?CTchesta(preferred)orchestx-ray?IfclinicallyindicatedpConsidercoreneedleebbiopsy(ebsuspected(eg,centralmass),considerurinecytology,ureteroscopyorPRIMARYTREATMENTd,eADJUVANTTPRIMARYTREATMENTd,eADJUVANTTREATMENTSTAGEFOLLOW-UPg(CATEGORY2B)orAblativetechniquesActivesurveillanceveillanceveillancefRadicalnephrectomy(inselectpatients)PartialnephrectomyRadicalnephrectomyorActivesurveillance(inselectpatients)D(Grade4tumorswithclearSeeKID-BistologyistologysarcomatoidStageIIaturesorRadicalnephrectomyveillanceflhistologyveillanceflhistologyAdjuvantpembrolizumabStageIIIorveillancefAdjuvantsunitinib(category3)Adjuvantsunitinib(category3)yallyindicatedStageIVSeeaImagingwithandwithoutcontrastisstronglypreferred,suchasarenalprotocol.bBiopsyofsmalllesionsmaybeconsideredtoobtainorconfirmadiagnosisofmalignancyandguidesurveillanceorablativetechniques,cryosurgery,andradiofrequencyablationstrategies.cIfmetastaticdiseaseispresentorthepatientcannottolerateureteroscopy.dSeePrinciplesofSurgery(KID-A).eStereotacticbodyradiotherapy(SBRT)maybeconsideredformedicallyinoperablepatientswithStageIkidneycancer(category2B)orwithStageII/IIIkidneycancer(bothcategory3).fSeeFollow-up(KID-B).gNosinglefollow-upplanisappropriateforallpatients.Follow-upshouldbeindividualizedbasedonpatientrequirements.Note:Allrecommendationsarecategory2Aunlessotherwiseindicated.ClinicalTrials:NCCNbelievesthatthebestmanagementofanypatientwithcancerisinaclinicaltrial.Participationinclinicaltrialsisespeciallyencouraged.KID-1Version1.2023,06/17/22?2022NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.PrintedbyMinTangon6/19/202210:53:22AM.Forpersonaluseonly.Notapprovedfordistribution.Copyright?2022NationalComprehensiveCancerNetwork,Inc.,AllRightsReserved.dexSTAGEPRIMARYTREATMENTdresectableprimaryhsamplingPotentiallysurgicallyresectableprimaryhsamplingentsCytoreductivenephrectomySeeKID-entsSystemictherapy(SeeKID-3)(preferredinclearcellhistologywithpoor-riskfeatures)StageIVSurgicallyunresectablehTissuesamplingSeeKID-3dSeePrinciplesofSurgery(KID-A).hIndividualizetreatmentbasedonsymptomsandextentofmetastaticdisease.Note:Allrecommendationsarecategory2Aunlessotherwiseindicated.ClinicalTrials:NCCNbelievesthatthebestmanagementofanypatientwithcancerisinaclinicaltrial.Participationinclinicaltrialsisespeciallyencouraged.KID-2Version1.2023,06/17/22?2022NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.PrintedbyMinTangon6/19/202210:53:22AM.Forpersonaluseonly.Notapprovedfordistribution.Copyright?2022NationalComprehensiveCancerNetwork,Inc.,AllRightsReserved.dexSIONClinicaltrialorSeeFirst-LineTherapy(KID-C,1of2)orMetastasectomyorSBRTorablativetechniquesforoligometastaticdiseaseorMetastasectomywithcompleteresectionofdisease,followedbyadjuvantpembrolizumabwithin1yearofnephrectomyststsupportivecareiFollow-upSeeKID-BClinicaltrialorSeeSubsequentTherapyforClearCellHistology(KID-C,1of2)ststsupportivecareiorMetastasectomyorSBRTorablativetechniquesforoligometastaticdiseaseNon-clearcellhistologyClinicaltrial(preferred)orSeeSystemicTherapy(KID-C,2of2)orstsupportivecareiMetastasectomyorSBRTorablativetechniquesforstsupportivecareiFollow-upSeeKID-BClinicaltrialorSeeSystemicTherapyforNon-ClearCellHistology(KID-C,2of2)ststsupportivecareiorMetastasectomyorSBRTorablativetechniquesforoligometastaticdiseaseBestsupportivecarecanincludepalliativeRTbisphosphonatesorRANKligandinhibitorsforbonymetastasesNote:Allrecommendationsarecategory2Aunlessotherwiseindicated.ClinicalTrials:NCCNbelievesthatthebestmanagementofanypatientwithcancerisinaclinicaltrial.Participationinclinicaltrialsisespeciallyencouraged.Version1.2023,06/17/22?2022NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.KID-3PrintedbyMinTangon6/19/202210:53:22AM.Forpersonaluseonly.Notapprovedfordistribution.Copyright?2022NationalComprehensiveCancerNetwork,Inc.,AllRightsReserved.dexPRINCIPLESOFSURGERY?Nephron-sparingsurgery(partialnephrectomy)isappropriateinselectedpatients,forexample:pUnilateralstageI–IIItumorswheretechnicallyfeasiblepUninephricstate,renalinsufficiency,bilateralrenalmasses,andfamilialrenalcellcancerpPatientsatrelativeriskfordevelopingprogressivechronickidneydiseaseduetoyoungageormedicalriskfactors(ie,hypertension,diabetes,nephrolithiasis)Openlaparoscopicorroboticsurgicaltechniquesmaybeusedtoperformradicalandpartialnephrectomies.Regionallymphnodedissectionisoptionalbutisrecommendedforpatientswithresectableadenopathyonpreoperativeimagingorpalpable/visibleadenopathyattimeofsurgery.?Ifadrenalglandisuninvolved,adrenalectomymaybeomitted.Specialteamsorreferraltohigh-volumecentersmayberequiredforextensiveinferiorvenacavainvolvement.?Thermalablation(eg,cryosurgery,radiofrequencyablation)isanoptionforthemanagementofpatientswithclinicalstageT1renallesions.pThermalablationisanoptionformasses<3cm,butmayalsobeanoptionforlargermassesinselectpatients.Ablationinmasses>3cmisassociatedwithhigherratesoflocalrecurrence/persistenceandcomplications.pBiopsyofsmalllesionsconfirmsadiagnosisofmalignancyforogicoutcomesasconventionalsurgeryabsurveillance,cryosurgery,andradiofrequencyablationstrategies.pogicoutcomesasconventionalsurgeryab?ActivesurveillanceisanoptionfortheinitialmanagementofpatientswithclinicalstageT1renallesions,forexample:pPatientswithsmallrenalmasses<2cmgiventhehighratesofbenigntumorsandlowmetastaticpotentialofthesemasses.pActivesurveillanceofpatientswithT1atumors(≤4cm)thathaveapredominantlycysticcomponentisrecommended.pPatientswithclinicalstageT1massesandsignificantcompetingrisksofdeathormorbidityfromintervention.pActivesurveillanceentailsserialabdominalimagingwithtimelyinterventionshouldthemassdemonstratechanges(eg,increasingtumorsize,growthrate,infiltrativepattern)indicativeofincreasingmetastaticpotential.pActivesurveillanceshouldincludeperiodicmetastaticsurveyincludingbloodworkandchestimaging,particularlyifthemassdemonstratesgrowth.?Generally,patientswhowouldbecandidatesforcytoreductivenephrectomypriortosystemictherapyhave:pExcellentperformancestatus(ECOGPS<2)pNobrainmetastasisaCampbellS,UzzoR,AllafM,etal.Renalmassandlocalizedrenalcancer:AUAGuideline.JUrol2017;198:520-529.bPierorazioP,JohnsonM,PatelH,etal.Managementofrenalmassesandlocalizedrenalcancer:Systematicreviewandmeta-analysis.JUrol2016;196:989-999.Note:Allrecommendationsarecategory2Aunlessotherwiseindicated.ClinicalTrials:NCCNbelievesthatthebestmanagementofanypatientwithcancerisinaclinicaltrial.Participationinclinicaltrialsisespeciallyencouraged.KID-AVersion1.2023,06/17/22?2022NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.KID-BOF5PrintedbyMinTangon6/19/202210:53:22AM.Forpersonaluseonly.Notapprovedfordistribution.Copyright?2022NationalComprehensiveCancerNetwork,Inc.,AllRightsKID-BOF5dexFOLLOW-UPa,byBStageI(T1a)Follow-upDuringActiveSurveillancec?H&Pannually?Laboratorytestsannually,asclinicallyindicated?Abdominalimaging:pAbdominalCTorMRIwithcontrastifnocontraindicationwithin6moofsurveillanceinitiation,thenCT,MRI,orultrasound(US)atleastannually?Chestimaging:pChestx-rayorCTatbaselineandannuallyasclinicallyindicatedtoassessforpulmonarymetastases?Considerrenalmassbiopsyatinitiationofactivesurveillanceoratfollow-up,asclinicallyindicated?Follow-upmaybeindividualizedbasedonsurgicalstatus,treatmentschedules,sideeffects,comorbidities,andsymptomsFollow-upAfterAblativeTechniquesc?H&Pannually?Laboratorytestsannually,asclinicallyindicated?Abdominalimaging:pAbdominalCTorMRIwithandwithoutIVcontrastat1–6mofollowingablativetherapyunlessotherwisecontraindicated,thenCTorMRI(preferred),orUSannuallyfor5yorlongerasclinicallyindicated.IfpatientisunabletoreceiveIVcontrast,MRIisthepreferredimagingmodalitypIfthereisimagingorclinicalconcernsforrecurrence,thenmorefrequentimaging,renalmassbiopsy,orfurthertreatmentmaybeindicated?Chestimaging:pChestx-rayorCTannuallyfor5yforpatientswhohavebiopsy-provenlow-riskrenalcellcarcinoma(RCC),nondiagnosticbiopsies,ornopriorbiopsyaDonatSM,DiazM,BishoffJT,etal.Follow-upforclinicallylocalizedrenalneoplasms:AUAGuideline.JUrol2013;190:407-416.bNosinglefollow-upplanisappropriateforallpatients.Follow-upfrequencyanddurationshouldbeindividualizedbasedonpatientrequirements,andmaybeextendedbeyond5years(SeeKID-B,5of5).Furtherstudyisrequiredtodefineoptimalfollow-upduration.cImagingwithcontrastwhenclinicallyindicated.Note:Allrecommendationsarecategory2Aunlessotherwiseindicated.ClinicalTrials:NCCNbelievesthatthebestmanagementofanypatientwithcancerisinaclinicaltrial.Participationinclinicaltrialsisespeciallyencouraged.Version1.2023,06/17/22?2022NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.PrintedbyMinTangon6/19/202210:53:22AM.Forpersonaluseonly.Notapprovedfordistribution.Copyright?2022NationalComprehensiveCancerNetwork,Inc.,AllRightsReserved.dexFOLLOW-UPa,byBStageI(pT1a)and(pT1b)cFollow-upAfteraPartialorRadicalNephrectomy?H&Pannually?Laboratorytestsannually,asclinicallyindicated?Abdominalimaging:pBaselineabdominalCTorMRI(preferred),orUSwithin3–12moofsurgery,thenannuallyfor3yorlongerasclinicallyindicatedpAmorerigorousimagingscheduleortechniquemodalitycanbeconsideredifpositivemarginsoradversepathologicfeatures(suchassarcomatoid,high-grade[grade3/4])?Chestimaging:pChestx-rayorCTannuallyforatleast5y,thenasclinicallyindicatedpAmorerigorousimagingscheduleortechniquemodalitycanbeconsideredifpositivemarginsoradversepathologicfeaturesaDonatSM,DiazM,BishoffJT,etal.Follow-upforclinicallylocalizedrenalneoplasms:AUAGuideline.JUrol2013;190:407-416.bNosinglefollow-upplanisappropriateforallpatients.Follow-upfrequencyanddurationshouldbeindividualizedbasedonpatientrequirements,andmaybeextendedbeyond5years(SeeKID-B,5of5).Furtherstudyisrequiredtodefineoptimalfollow-upduration.cImagingwithcontrastwhenclinicallyindicated.Note:Allrecommendationsarecategory2Aunlessotherwiseindicated.ClinicalTrials:NCCNbelievesthatthebestmanagementofanypatientwithcancerisinaclinicaltrial.Participationinclinicaltrialsisespeciallyencouraged.Version1.2023,06/17/22?2022NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.KID-B2OF5PrintedbyMinTangon6/19/202210:53:22AM.Forpersonaluseonly.Notapprovedfordistribution.Copyright?2022NationalComprehensiveCancerNetwork,Inc.,AllRightsReserved.dexFOLLOW-UPa,byBFollow-upforStageIIorIII?H&Pevery3–6mofor3y,thenannuallyupto5y,andasclinicallyindicatedthereafter?Comprehensivemetabolicpanelandothertestsasindicatedevery3–6mofor3y,thenannuallyupto5y,andasclinicallyindicatedthereafter?Abdominalimaging:pBaselineabdominalCTorMRIwithin3–6mo,thenCTorMRI(preferred),orUS(USiscategory2BforstageIII),every3–6moforatleast3yandthenannuallyupto5ypImagingbeyond5y:asclinicallyindicated?Chestimaging:pBaselinechestCTwithin3–6mowithcontinuedimaging(CTpreferred)every3–6moforatleast3yandthenannuallyupto5ypImagingbeyond5y:asclinicallyindicatedbasedonindividualpatientcharacteristicsandtumorriskfactors?Additionalimaging(ie,bonescan,brainimaging):pAssymptomswarrantaDonatSM,DiazM,BishoffJT,etal.Follow-upforclinicallylocalizedrenalneoplasms:AUAGuideline.JUrol2013;190:407-416.bNosinglefollow-upplanisappropriateforallpatients.Follow-upfrequencyanddurationshouldbeindividualizedbasedonpatientrequirements,andmaybeextendedbeyond5years(SeeKID-B,5of5).Furtherstudyisrequiredtodefineoptimalfollow-upduration.Note:Allrecommendationsarecategory2Aunlessotherwiseindicated.ClinicalTrials:NCCNbelievesthatthebestmanagementofanypatientwithcancerisinaclinicaltrial.Participationinclinicaltrialsisespeciallyencouraged.Version1.2023,06/17/22?2022NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenper
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網頁內容里面會有圖紙預覽,若沒有圖紙預覽就沒有圖紙。
- 4. 未經權益所有人同意不得將文件中的內容挪作商業(yè)或盈利用途。
- 5. 人人文庫網僅提供信息存儲空間,僅對用戶上傳內容的表現(xiàn)方式做保護處理,對用戶上傳分享的文檔內容本身不做任何修改或編輯,并不能對任何下載內容負責。
- 6. 下載文件中如有侵權或不適當內容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準確性、安全性和完整性, 同時也不承擔用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 2025年珠寶行業(yè)虛假鑒定查處考核試卷
- 2025年快遞自動分揀設備參數(shù)調試操作考核試卷
- 2025年網絡視聽節(jié)目海外傳播合規(guī)傳媒行業(yè)文化產業(yè)發(fā)展考核試卷
- 2025年綠色建筑能源系統(tǒng)全生命周期評價考核試卷
- 三峽核協(xié)議書
- 無償股權轉讓協(xié)議書
- 西山區(qū)畢業(yè)活動策劃方案
- 三年不能離職協(xié)議書
- 糧食加工廠原材料采購合同
- 2025-2030企業(yè)直播SaaS功能需求分層與客戶畫像報告
- 人工智能基礎與應用(第2版)全套教學課件
- 收銀標準化培訓課件
- 高血壓與氣溫的關系
- 大學生活與高中生活的對比分析
- 《同人作品著作權法律問題研究》
- (新版標準日本語初級下冊)第25課 教學課件 知識點+練習
- 德國企業(yè)的共同治理模式
- 集成電路器件與SPICE模型9
- 民宿經營管理培訓教材
- 住院醫(yī)師規(guī)范化培訓臨床實踐能力結業(yè)考核專科技能操作評分表(皮膚科)真菌鏡檢
- 2022年宜昌市不動產登記中心事業(yè)單位工作人員招聘筆試試題及答案
評論
0/150
提交評論